Atnahs Buys Takeda Out of License Agreement for Bonviva^® in Asia

Basildon (UK), 6 February 2020 – Atnahs has bought Takeda out of a license agreement for Bonviva^® (Ibandronic acid) in seven selected Asian markets. Bonviva^® is used to treat osteoporosis in post-menopausal women. Terms and conditions of the transaction are not disclosed.

Founded in 2013, Atnahs has significantly increased its product portfolio since inception through its strong relationships with leading biopharmaceutical companies such as Takeda.

The acquisition expands Atnahs’ ownership of Bonviva^® to include Hong Kong, Macau, Malaysia, the Philippines, Singapore, Taiwan and Vietnam, where Bonviva^® has been serving patients as an established brand with a high market share.

“The acquisition is a further step in the expansion of our product portfolio, in particular, to build on our offering in Women’s Health as well as our global footprint. Bonviva^® is a highly renowned brand in Asia, which underlines our goal to deliver medicines that patients, prescribers, healthcare systems and regulators value”, says Dr. Amit Patel, CEO of Atnahs.

About Atnahs

Atnahs is a specialty pharmaceutical business, focused on acquiring mature branded medicines out of large cap and specialty pharma companies globally and developing its own niche medicines. Atnahs operates a portfolio of 21 brands with over 1,900 SKUs across more than 140 markets, with a focus on therapeutic areas such as Women’s Health, Pain, Oncology and Cardiovascular.

For further information: www.atnahs.com